Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action

摘要: We tried to review and update clinical preclinical studies evaluating vilazodone's role as an antidepressant for patients with major depressive disorder (MDD). In terms of its mechanism actions, we sought elaborate them mainly through animal studies. A data search was conducted in November 1, 2013, using the key "vilazodone" or "Viibryd," PubMed Medline databases. All published unpublished are included citations from publications were also reviewed additional references. Five unpublished, phase-II two pivotal phase-III trials nearly identical design (8-week, double-blind, randomized, placebo-controlled) investigated efficacy vilazodone, found treatment MDD. Two post-hoc one long-term open study included. Data thoroughly incorporate pharmacology, action mechanism, safety vilazodone disorder. Vilazodone is novel because chemical structure unrelated conventional antidepressant, it has a selective serotonin (5-HT) reuptake inhibitor 5-HT1A receptor partial agonist profile. effective safe option mechanisms depression. Its putative benefits compared other antidepressants must be studied adequately-powered well-designed future trials.